Table 2.

Results of LMB-2 preceded by fludarabine and cyclophosphamide

PatientFludarabineCyclophosphamideLMB-2a (μg/kg) d3, 5, 7Total cycles givenBest responseResponse duration (wk)Time (wk) toLMB-2 immunogenicity
(mg/m2) d1, 2, 3CRPRCRPR
CF0125250N/A1NENE
CF0225250303SDN
CF0325250305CR15304.74.7Y
CF0425250303SDN
CF0525250405PR9614.0Y
CF0625250402PDN
CF0725250403SDN
CF08b30300404CR62655.11.9Y
CF0930300403PR81.7N
CF1025250407CR203+207+4.70.6N
CF1125250402PDN
CF12c25250407CR71745.31.6N
CF1325250407CR1910810.61.7Y
CF14d25250405CR12154.41.7N
CF1520200N/A1NENE
CF1620200403SDN
CF1720200402PDNE
  • aLMB-2 began with cycle 2.

  • bCF08 received fludarabine and cyclophosphamide but no LMB-2 for cycle 4.

  • cCF12 received cyclophosphamide 200 mg/m2 for cycle 3 and no fludarabine and cyclophosphamide thereafter.

  • dCF14 received no fludarabine and cyclophosphamide after cycle 2.